Mexico Tees Up Moderna’s Local mRNA Production for Respiratory Vaccines, Shares Dive on Rejection
Mexico has enlisted Moderna to expand local manufacturing of mRNA vaccines for respiratory diseases, establishing a production line to address influenza and RSV demands. Moderna shares plunged after an unnamed regulatory agency rejected its respiratory vaccine candidate, prompting management to urgently seek clarification on the decision’s commercial impact.
1. Mexico partnership
Mexico’s federal government has signed an agreement with Moderna to establish a dedicated mRNA vaccine manufacturing facility within the country. The move aims to secure domestic supply of next-generation vaccines targeting respiratory pathogens such as influenza and RSV, reducing reliance on imports and bolstering regional pandemic preparedness.
2. Vaccine rejection
Moderna’s stock suffered a sharp decline after an unnamed regulatory agency declined its latest respiratory vaccine application, raising concerns over the product’s approval pathway. The company has formally requested detailed feedback on the decision and is evaluating its options to address regulatory requirements and reassure investors.